{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:37:20Z","timestamp":1791301040504,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>A substantial proportion of locally advanced head-and-neck squamous cell cancer (LAHNSCC) patients remain ineligible for cisplatin-based chemoradiation due to its frequent toxicities. The study was conducted to compare carboplatin plus capecitabine versus 3-weekly cisplatin in LAHNSCC patients undergoing definitive chemoradiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this phase II randomized trial, stage 3 or 4 laryngeal or pharyngeal cancer patients received radiation dose of 66\u201370 gray in 33\u201335 fractions and were randomized (1:1) to weekly carboplatin (AUC 1.5) plus capecitabine 850 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day on the radiation days versus 3-weekly cisplatin (50 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 1 and day 2). The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Secondary endpoints included grade \u2265 3 treatment toxicities and treatment interruption rate (TIR). The study is registered with CTRI number CTRI\/2020\/11\/029290.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 81 patients were studied, 40 in the experimental and 41 in the control arm. At a median follow-up of 12.5 months, the median PFS was 14 months versus 12.5 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.715). The ORR was 97.5% versus 94.7%, whereas the complete response rate was 57.5% versus 42.1% in the experimental and control arm, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.449). Significantly lower grade \u22653 toxicity was observed in the experimental arm, i.e., oral mucositis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.000), vomiting (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.000), nephropathy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014), dyselectrolytemia (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013), fatigue (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006), anorexia (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). The TIR was significantly lower in the experimental arm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.000).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Carboplatin plus capecitabine-based chemoradiation shows similar efficacy with lesser toxicity compared to 3-weekly cisplatin-based chemoradiation in LAHNSCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2510_24","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:00:27Z","timestamp":1758906027000},"page":"1032-1037","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Phase-II randomized study of carboplatin plus capecitabine versus 3-weekly cisplatin in locally advanced head-and-neck cancer patients undergoing concurrent chemoradiation (CARCAP-HN)"],"prefix":"10.4103","volume":"21","author":[{"given":"Srigopal","family":"Mohanty","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, HCG Cancer Centre, Cuttack, Orissa, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallolinee","family":"Samal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G. D.","family":"Gangadaran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Selvarangam Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaraman","family":"Kannan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Madras Medical College, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ramkumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kilpauk Medical College, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Saravanan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kilpauk Medical College, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"R1-20250929","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/GO.20.00122","article-title":"ICMR-NCDIR-NCRP investigator group. Cancer Statistics 2020:Report from National Cancer Registry Programme, India","volume":"6","author":"Mathur","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"R2-20250929","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-20250929","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1093\/annonc\/mds065","article-title":"Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma:10-year results of EORTC trial 24891","volume":"23","author":"Lefebvre","year":"2012","journal-title":"Ann Oncol"},{"key":"R4-20250929","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1998.16.4.1318","article-title":"Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer:A randomized multicenter study","volume":"16","author":"Wendt","year":"1998","journal-title":"J Clin Oncol"},{"key":"R5-20250929","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"R6-20250929","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hed.23865","article-title":"Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck:Results of a prospective randomized trial","volume":"38","author":"Ghosh-Laskar","year":"2016","journal-title":"Head Neck"},{"key":"R7-20250929","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.1994.12.12.2648","article-title":"Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer","volume":"12","author":"Browman","year":"1994","journal-title":"J Clin Oncol"},{"key":"R8-20250929","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/88.9.583","article-title":"Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck","volume":"88","author":"Merlano","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R9-20250929","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","article-title":"Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer","volume":"338","author":"Brizel","year":"1998","journal-title":"N Engl J Med"},{"key":"R10-20250929","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer","volume":"355","author":"Pignon","year":"2000","journal-title":"Lancet"},{"key":"R11-20250929","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.ijrobp.2007.04.088","article-title":"Meta-analyses of chemotherapy in head and neck cancer (MACH-NC):An update","volume":"69","author":"Pignon","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20250929","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC):An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"key":"R13-20250929","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/14656566.4.6.889","article-title":"Toxicity of platinum compounds","volume":"4","author":"Hartmann","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"R14-20250929","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3892\/or.2013.2279","article-title":"Correlation of adverse effects of cisplatin administration in patients affected by solid tumors:A retrospective evaluation","volume":"29","author":"Astolfi","year":"2013","journal-title":"Oncol Rep"},{"key":"R15-20250929","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.18632\/oncotarget.6858","article-title":"A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)","volume":"7","author":"Guan","year":"2016","journal-title":"Oncotarget"},{"key":"R16-20250929","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5582\/ddt.2013.v7.1.36","article-title":"Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer","volume":"7","author":"Gupta","year":"2013","journal-title":"Drug Discov Ther"},{"key":"R17-20250929","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1177\/014556131609500210","article-title":"Concurrent chemoradiotherapy with capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma","volume":"95","author":"Ahn","year":"2016","journal-title":"Ear Nose Throat"},{"key":"R18-20250929","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/sj.bjc.6602275","article-title":"Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors","volume":"91","author":"Hitt","year":"2004","journal-title":"Br J Cancer"},{"key":"R19-20250929","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.bjc.6602849","article-title":"Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"93","author":"Kim","year":"2005","journal-title":"Br J Cancer"},{"key":"R20-20250929","first-page":"2869","article-title":"Phase I study of capecitabine, carboplatin and intensity modulated radiation therapy for head and neck cancer","volume":"29","author":"Thomas","year":"2009","journal-title":"Anticancer Res"},{"key":"R21-20250929","first-page":"681","article-title":"Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma","volume":"32","author":"Komatsu","year":"2012","journal-title":"Anticancer Res"},{"key":"R22-20250929","doi-asserted-by":"crossref","first-page":"102585","DOI":"10.1016\/j.ctrv.2023.102585","article-title":"Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck:Is there a standard of care?","volume":"119","author":"Haddad","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"R23-20250929","doi-asserted-by":"crossref","first-page":"799","DOI":"10.31557\/APJCP.2020.21.3.799","article-title":"Cisplatin weekly versus every 3 weeks concurrently with radiotherapy in the treatment of locally advanced head and neck squamous cell carcinomas:What is the best dosing and schedule?","volume":"21","author":"Mashhour","year":"2020","journal-title":"Asian Pac J Cancer Prev"},{"key":"R24-20250929","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2019.00086","article-title":"Low dose vs. high dose cisplatin:Lessons learned from 59 chemoradiotherapy trials in head and neck cancer","volume":"9","author":"Szturz","year":"2019","journal-title":"Front Oncol"},{"key":"R25-20250929","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once a week versus once every 3 weeks cisplatin chemoradiation for locally advanced head and neck cancer:A phase III randomized non inferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20250929","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1748-717X-7-215","article-title":"The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity","volume":"7","author":"Tsan","year":"2012","journal-title":"Radiat Oncol"},{"key":"R27-20250929","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3389\/fonc.2020.00761","article-title":"Comparison of carboplatin with 5-fluorouracil vs. cisplatin as concomitant chemoradiotherapy for locally advanced head and neck squamous cell carcinoma","volume":"10","author":"Hanemaaijer","year":"2020","journal-title":"Front Oncol"},{"key":"R28-20250929","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2016.04.003","article-title":"Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?","volume":"57","author":"Rades","year":"2016","journal-title":"Oral Oncol"},{"key":"R29-20250929","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.ijrobp.2007.07.2380","article-title":"Locally advanced stage IV squamous cell carcinoma of the head and neck:Impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy","volume":"70","author":"Rades","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20250929","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.radonc.2020.12.025","article-title":"Prolongation of definitive head and neck cancer radiotherapy:Survival impact and predisposing factors","volume":"156","author":"Xiang","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2510_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:49Z","timestamp":1787068129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2510_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2510_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-12-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}